AstraZeneca (AZN), Espress Scripts (ESRX) Announce First D-T-P Program for ARIMIDEX Patients
Tweet
Share
E-mailGet Alerts AZN Hot Sheet
Join SI Premium – FREE
AstraZeneca (NYSE: AZN) today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts (Nasdaq: ESRX), a specialty pharmacy services provider, for $40 per month, including shipping.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
- BIGG Digital Assets to rename as Surge Digital, consolidate shares
- Denarius Metals acquires 15% stake in Copper Giant, Trafigura invests
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
